PharmExtracta Probiotic Wins Womens Health Award, Targets Pregnancy Microbiome Support

Barcelona, Spain — 21 May 2026

PharmExtracta's iNatal, a precision probiotic formulated for maternal health during pregnancy, has been awarded the 2026 NutraIngredients Award for Innovation in Women's Health. This recognition highlights a shift towards scientifically grounded solutions for vaginal and intestinal microbiota support in expectant mothers.

The formulation combines four specific probiotic strains: Enterococcus faecium L3, Bifidobacterium animalis subsp. lactis BB-12, Lactobacillus casei RO215, and Lactococcus lactis SP38. Judges commended iNatal for its potential to reduce reliance on antibiotics and address common gynaecological infections during pregnancy. Clinical data from a controlled study involving 250 pregnant women demonstrated a 67% reduction in premature rupture of membranes (PROM) and a 29% decrease in antibiotic usage. Furthermore, the study reported a 33% reduction in Group B Streptococcus, mitigating potential complications during labour.

Elena Fava, International Product Manager at PharmExtracta, emphasised that success stems from a 'precision probiotic' approach, distinct from typical blends. The product's multi-impact nature, addressing gastrointestinal balance, bloating, and vertical transmission of optimal neonatal microbiota, has garnered significant professional confidence, particularly among Italian gynaecologists and midwives.

The award underscores an accelerating trend in women's health innovation, with products increasingly focusing on specific life-stage challenges like fertility, pregnancy, and menopause. This market segment demands robust clinical substantiation and clear differentiation to drive commercial interest, even amidst declining birth rates in some regions. Products offering dual benefits for mother and baby, supported by rigorous trials, are poised for strong market traction.

What this means for Italy

Italian manufacturers and brand owners should note iNatal's success as a benchmark for product development. Given PharmExtracta's existing strong relationships with Italian gynaecologists, brand owners targeting prenatal care must invest in clinical studies that demonstrate concrete reductions in adverse pregnancy outcomes like PROM or GBS. Regulatory teams should prepare for increased scrutiny on probiotic claims, necessitating dossier compilation that aligns with EFSA guidelines for health claims, even if not direct. This award creates a competitive advantage for precise, multi-strain formulations over generic probiotic blends, influencing procurement decisions and reformulations to capture market share within the estimated €180 million Italian maternal health supplement market.

This trend is being actively addressed by UK manufacturing partners including Supplement Factory.